Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.60 |
| ▸ | GRM5 | P41594 | 9/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.45 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL981457 | 0.91 | PTGES (0.74) | PTGESGRM5P4HTM | |
| SCHEMBL979176 | 0.88 | PTGES (0.78) | PTGESPTGS2PTGS1EGFR | |
| SCHEMBL979893 | 0.86 | PTGES (0.57) | PTGESGRM5PTGS2P4HTM | |
| SCHEMBL2806398 | 0.82 | PTGES (0.64) | PTGESGRM5P4HTM | |
| SCHEMBL981304 | 0.81 | PTGES (0.56) | PTGESGRM5P4HTM | |
| SCHEMBL976643 | 0.80 | PTGES (0.55) | PTGESGRM5P4HTM | |
| SCHEMBL13850790 | 0.80 | P4HTM (0.52) | PTGESPTGS2P4HTMPTGS1EGFR | |
| SCHEMBL980273 | 0.80 | PTGES (0.74) | PTGESGRM5P4HTM | |
| SCHEMBL977518 | 0.78 | PTGES (0.56) | PTGESGRM5P4HTM | |
| SCHEMBL976823 | 0.76 | PTGES (1.00) | PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2011-01-27 | — | — | US | claimed |
| CN-101910121-A | Bis (sulfonylamino) derivatives 066 in therapy | ASTRAZENECA AB | 2010-12-08 | — | — | CN | claimed |
| EP-2217566-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | AstraZeneca AB (SE) | 2010-08-18 | — | — | EP | claimed |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | US | claimed |
| WO-2009064250-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 065 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | claimed |
| WO-2009064251-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | claimed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | claimed |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2011-01-27 | — | — | US | disclosed |
| CN-101910121-A | Bis (sulfonylamino) derivatives 066 in therapy | ASTRAZENECA AB | 2010-12-08 | — | — | CN | disclosed |
| EP-2217566-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | AstraZeneca AB (SE) | 2010-08-18 | — | — | EP | disclosed |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | US | disclosed |
| WO-2009064250-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 065 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064251-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | PTGER1, CYP3A5, SULT1E1 | PTGES 9/4885GRM5 456/4885PTGS2 41/4885 |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | CYP2D6, PTGER1, CYP2B6 | PTGES 13/4885GRM5 1882/4885PTGS2 47/4885 |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | CYP2D6, PTGER1, CYP2B6 | PTGES 13/4885GRM5 1882/4885PTGS2 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.